このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
United Therapeutics バランスシートの健全性
財務の健全性 基準チェック /66
United Therapeuticsの総株主資本は$5.3B 、総負債は$600.0Mで、負債比率は11.2%となります。総資産と総負債はそれぞれ$6.5Bと$1.2Bです。 United Therapeuticsの EBIT は$1.3Bで、利息カバレッジ比率-9.8です。現金および短期投資は$2.7Bです。
主要情報
11.2%
負債資本比率
US$600.00m
負債
| インタレスト・カバレッジ・レシオ | -9.8x |
| 現金 | US$2.71b |
| エクイティ | US$5.34b |
| 負債合計 | US$1.16b |
| 総資産 | US$6.50b |
財務の健全性に関する最新情報
Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20Recent updates
United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely
Jul 17United Therapeutics reaches all-time high; shares up 15% YTD
Jul 06Why Hold United Therapeutics After Shares Doubled?
Jun 08With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Is Interesting
May 06財務状況分析
短期負債: UTHRの 短期資産 ( $3.2B ) が 短期負債 ( $860.6M ) を超えています。
長期負債: UTHRの短期資産 ( $3.2B ) が 長期負債 ( $296.5M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: UTHR総負債よりも多くの現金を保有しています。
負債の削減: UTHRの負債対資本比率は、過去 5 年間で45.3%から11.2%に減少しました。
債務返済能力: UTHRの負債は 営業キャッシュフロー によって 十分にカバー されています ( 163.3% )。
インタレストカバレッジ: UTHR支払う利息よりも稼ぐ利息の方が多いので、利息支払い の補償は問題になりません。